Following the agreement, it has reached with Université Laval and the CERVO Brain Research Centre of the CIUSSS de la Capitale Nationale, the venture capital fund will finance the development of a project on the SRSF3 target in the laboratory of Dr Jasna Kriz.
AmorChem is based Montreal, and focused on creating promising life science companies from technologies originating primarily from Quebec-based universities and research centres.
Launched in 2011, the AmorChem I Fund model combines access to financial resources with a virtual incubator structure that enables the rapid development and commercialisation of its technologies.
The first fund (41.2MUSD) has built a portfolio of 24 technologies and successfully transacted two pharma exits as well as spun-out six companies. The attractiveness of this seed fund model and the role it plays in the investment ecosystem were highlighted in September 2017 with the launch of the AmorChem II Fund, which now totals USD 45.7m.
Abilita Bio signs multi-target collaboration with Amgen
Innovent treats first cancer patient in Phase I clinical trial of Anti-OX40 Antibody
Parexel Appoints Former FDA Senior Executives to Global Regulatory Consulting Services
Victa Biotherapeutics Appoints Kufe to Board of Directors
US Patent Issued for AXA Candidate AXA1125
Omeros Names Bumol to Board of Directors
Bicycle Therapeutics Awarded GBP 496,000 SBRI Contract to Address Antimicrobial Resistance in Humans